Fatal delayed thrombocytopenia following abciximab therapy

Journal of Invasive Cardiology

Volumn 18, Issue 6, 2006, Pages

  McCorry, Roger B ^a,b   Johnston, Paul ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ATORVASTATIN; BISOPROLOL; CLOPIDOGREL; ENOXAPARIN; ESCITALOPRAM; HEPARIN; RAMIPRIL; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTERY OCCLUSION; ARTICLE; CASE REPORT; CLINICAL FEATURE; CORONARY STENT; DRUG DOSE REGIMEN; ELECTROCARDIOGRAM; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MALE; ST SEGMENT ELEVATION; THORAX PAIN; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY ATHEROSCLEROSIS; FATALITY; THROMBOCYTE COUNT; TIME;

ADULT; ANGIOPLASTY; ANTIBODIES, MONOCLONAL; CHEST PAIN; CORONARY ARTERIOSCLEROSIS; FATAL OUTCOME; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; THROMBOCYTOPENIA; TIME FACTORS;

EID: 33747126170     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions: The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-847.
2. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36:75-83.
3. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: Results of the ReoPro readministration registry. Circulation 2001;104:870-875
4. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005;127(2 Suppl):53S-59S.
5. Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004;2:985-992.
6. Nurden P, Clofent-Sanchez G, Jais C, et al. Delayed immunologic thrombocytopenia induced by abciximab. Thromb Haemost 2004;92:820-828.
7. Reddy MS, Carmody TJ, Kereiakes DJ. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovasc Interv 2001;52:486-488.
8. Kaluski E, Leitman M, Khiger I, Cotter G. Delayed thrombocytopenia following abciximab therapy. Int J Cardiovasc Intervent 2001;4:151-155.
9. Sharma S, Bhambi B, Nyitray W, et al. Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro). J Cardiovasc Pharmacol Ther 2002;7:21-24.
10. Jenkins LA, Lau S, Crawford M, Keung YK. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1998;97:1214-1215.